Oridonin inhibits bladder cancer survival and immune escape by covalently targeting HK1
- 7 February 2024
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 126, 155426
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 45 references indexed in Scilit:
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activityNature Communications, 2018
- c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasisNature Communications, 2017
- Oridonin promotes G2/M arrest in A549 cells by facilitating ATM activationMolecular Medicine Reports, 2016
- Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compoundsSeminars in Cancer Biology, 2016
- Metabolic phenotype of bladder cancerCancer Treatment Reviews, 2016
- Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenicProceedings of the National Academy of Sciences, 2015
- Targeting glycogen metabolism in bladder cancerNature Reviews Urology, 2015
- A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL modelsNature Chemical Biology, 2015
- Rapid Identification of Monospecific Monoclonal Antibodies Using a Human Proteome MicroarrayMolecular & Cellular Proteomics, 2012
- Drug Bioactivation Covalent Binding to Target Proteins and Toxicity RelevanceDrug Metabolism Reviews, 2005